

Low-dose aspirin does not cut death from prostate cancer

5 March 2019



interval, 1.05 to 1.20). Prostate cancer mortality was slightly reduced with postdiagnosis exposure to low-dose aspirin periods of five years (aHR, 0.91; 95 percent confidence interval, 0.83 to 1.01) and 7.5 years (aHR, 0.84; 95 percent confidence interval, 0.72 to 0.97), particularly among patients filling prescriptions for a large quantity of low-dose aspirin tablets during the 7.5-year period.

"Results for extended exposure periods suggest that low-dose aspirin use might be inversely associated with [prostate cancer mortality](#) after five years from [cancer](#) diagnosis," the authors write.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)
[Editorial \(subscription or payment may be required\)](#)

Copyright © 2019 [HealthDay](#). All rights reserved.

(HealthDay)—Low-dose aspirin use does not appear to reduce the overall risk for prostate cancer death, according to a study published online March 5 in the *Annals of Internal Medicine*.

Charlotte Skriver, from the Danish Cancer Society Research Center in Copenhagen, and colleagues used a nationwide data registry to assess the association between postdiagnosis use of low-dose aspirin (at least two prescriptions [75 to 150 mg] filled within one year after prostate [cancer diagnosis](#)) and prostate cancer mortality. The authors note that 29,136 patients were diagnosed from 2000 through 2011.

During a median of 4.9 years of follow-up, 7,633 patients died of prostate cancer and 5,575 died of other causes. The researchers observed an association between postdiagnosis low-dose aspirin use and [prostate cancer](#)-specific mortality (adjusted hazard ratio [aHR], 0.95; 95 percent confidence interval, 0.89 to 1.01) and other-cause mortality (aHR, 1.12; 95 percent confidence

APA citation: Low-dose aspirin does not cut death from prostate cancer (2019, March 5) retrieved 28 April 2021 from <https://medicalxpress.com/news/2019-03-low-dose-aspirin-death-prostate-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.